Psychemedics (PMDI) 10-K 16 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 16, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	PSYCHEMEDICS CORP
Entity Central Index Key	806,517
Trading Symbol	pmd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		5,492,053
Entity Public Float			$ 107
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 8,165	$ 3,938
Accounts receivable, net of allowance for doubtful accounts of $64 in 2017 and $50 in 2016	4,488	5,837
Prepaid expenses and other current assets	1,212	1,079
Total Current Assets	13,865	10,854
Property and equipment:
Computer software	3,614	3,085
Office furniture and equipment	1,961	1,680
Laboratory equipment	15,504	15,182
Leasehold improvements	2,402	2,311
Property and equipment - gross	23,481	22,258
Less–accumulated depreciation and amortization	(11,670)	(8,900)
Property and equipment - net	11,811	13,358
Other assets	832	820
Total Assets	26,508	25,032
Current Liabilities:
Accounts payable	398	1,363
Accrued expenses	2,870	1,988
Current portion of long-term debt	957	1,144
Total Current Liabilities	4,225	4,495
Long-term debt	2,420	2,237
Deferred tax liabilities, long-term	1,243	2,693
Total Liabilities	7,888	9,425
Commitments and Contingencies (Note 9)
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding
Common stock, $0.005 par value; 50,000 shares authorized 6,160 shares issued in 2017 and 6,128 shares issued 2016, 5,492 shares outstanding in 2017 and 5,460 shares outstanding in 2016	31	31
Accumulated other comprehensive loss	(238)
Additional paid-in capital	31,022	30,603
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated deficit	(2,113)	(4,945)
Total Shareholders' Equity	18,620	15,607
Total Liabilities and Shareholders' Equity	$ 26,508	$ 25,032

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Allowance for doubtful accounts	$ 64	$ 50
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	873	873
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, share issued (in shares)	6,160	6,128
Common stock, shares outstanding (in shares)	5,492	5,460
Treasury stock, shares (in shares)	668	668

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 39,701	$ 38,980	$ 26,975
Cost of revenues	19,879	17,530	14,258
Gross profit	19,822	21,450	12,717
Operating Expenses:
General & administrative	5,642	4,965	4,561
Marketing & selling	4,666	4,960	5,053
Research & development	1,357	1,415	1,632
Total Operating Expenses	11,665	11,340	11,246
Operating income	8,157	10,110	1,471
Other income (expense)	20	(134)	(124)
Net income before provision for income taxes	8,177	9,976	1,347
Provision for / (benefit from) income taxes	2,056	3,298	(164)
Net income	6,121	6,678	1,511
Other Comprehensive Income (Loss):
Foreign currency translation	(238)
Total Comprehensive Income (Loss)	$ 5,883	$ 6,678	$ 1,511
Basic net income per share (in dollars per share)	$ 1.12	$ 1.23	$ 0.28
Diluted net income per share (in dollars per share)	1.10	1.22	0.28
Dividends declared per share (in dollars per share)	$ 0.60	$ 0.60	$ 0.60

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2014	6,043		668
Balance at Dec. 31, 2014	$ 30	$ 29,454	$ (10,082)	$ (6,566)		$ 12,836
Shares issued – vested (in shares)	40
Exercise of stock options (in shares)	8
Exercise of stock options		61				61
Tax withholding related to vested shares from employee stock plans		(227)				(227)
Stock compensation expense		674				674
Excess tax benefit from stock-based compensation plans		60				60
Cash dividends declared ($0.60 per share)				(3,241)		(3,241)
Net income				1,511		1,511
Other comprehensive loss
Balance (in shares) at Dec. 31, 2015	6,091		668
Balance at Dec. 31, 2015	$ 30	30,022	$ (10,082)	(8,296)		11,674
Shares issued – vested (in shares)	37
Tax withholding related to vested shares from employee stock plans		(202)				(202)
Stock compensation expense		671				671
Excess tax benefit from stock-based compensation plans		113		(60)		53
Cash dividends declared ($0.60 per share)				(3,267)		(3,267)
Net income				6,678		6,678
Shares issued – vested	$ 1	(1)
Other comprehensive loss
Balance (in shares) at Dec. 31, 2016	6,128		668
Balance at Dec. 31, 2016	$ 31	30,603	$ (10,082)	(4,945)		$ 15,607
Shares issued – vested (in shares)	32
Exercise of stock options (in shares)						2
Exercise of stock options		35				$ 35
Tax withholding related to vested shares from employee stock plans		(198)				(198)
Stock compensation expense		582				582
Cash dividends declared ($0.60 per share)				(3,289)		(3,289)
Net income				6,121		6,121
Other comprehensive loss					$ (238)	(238)
Balance (in shares) at Dec. 31, 2017	6,160		668
Balance at Dec. 31, 2017	$ 31	$ 31,022	$ (10,082)	$ (2,113)	$ (238)	$ 18,620

Consolidated Statements of Sha6

Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Common Stock [Member]
Dividends declared per share (in dollars per share)	$ 0.60	$ 0.60	$ 0.60
Dividends declared per share (in dollars per share)	$ 0.60	$ 0.60	$ 0.60

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ 6,121	$ 6,678	$ 1,511
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,807	2,294	1,731
Deferred income taxes	(1,450)	168	105
Stock compensation expense	582	671	674
Changes in operating assets and liabilities:
Accounts receivable	1,316	(2,298)	539
Prepaid expenses, other current assets and income tax receivable	(133)	822	609
Accounts payable	(990)	144	(98)
Accrued expenses	893	790	(491)
Net cash provided by operating activities	9,146	9,269	4,580
Cash flows from investing activities:
Increase in long-term assets; capitalized patent costs	(49)	(82)	(46)
Purchases of property and equipment and capitalized software development costs	(1,197)	(2,012)	(1,752)
Net cash used in investing activities	(1,246)	(2,094)	(1,798)
Cash flows from financing activities:
Dividends paid	(3,289)	(3,267)	(3,241)
Proceeds from stock options and tax withholding related to vested shares from employee stock plans	(163)	(149)	(106)
Proceeds from equipment financing	2,078	610	1,097
Payments of equipment financing	(2,082)	(3,120)	(1,455)
Net cash used in financing activities	(3,456)	(5,926)	(3,705)
Effect of exchange rate changes on cash and cash equivalents	(217)
Net increase (decrease) in cash and cash equivalents	4,227	1,249	(923)
Cash and cash equivalents, beginning of year	3,938	2,689	3,612
Cash and cash equivalents, end of year	8,165	3,938	2,689
Supplemental disclosures of cash flow information:
Cash paid for income taxes	2,824	1,814	40
Cash paid for interest	70	134	128
Non-cash investing and financing activities:
Purchases of equipment through accounts payable and accrued liabilities	$ 25	$ 472	$ 338

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune 500

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. Cash Equivalents All highly liquid investments with original maturities of 90 December 31, 2017, $4.6 December 31, 2016 2015, no Fair Value Measurements The Company follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures 820” 820 820 three first two may Level 1 Level 2 1 Level 3 no A financial instrument’s level is based on the lowest level of any input that is significant to the fair value measurement. Inventory Some materials used in the provision of services to our customers are included in prepaid expenses and recorded to cost of revenues upon use. Most consumables such as chemicals, antibodies and tubes are expensed as purchased. Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software (in years) 3 to 5 Office furniture and equipment (in years) 3 to 7 Laboratory equipment (in years) 5 to 7 Leasehold improvements (in years) Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.8 $2.3 $1.7 2017, 2016 2015 December 31, 2017 2016, $0.5 $1.2 not Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for 5 December 31, 2017, 2016 2015, $511, $315 $364, $418, $435 $422 2017, 2016, 2015, may Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2017, 2016, 2015 $711, $715 $670, $37, $36, $32 2017, 2016 2015, $50 five Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. The Company records revenue for the shipping of samples from the customer or independent hair collection facility to the laboratory for customers that choose to use the Company’s shipping account. The Company also records revenue for the collection of the hair sample for customers that choose to have the Company manage this process at the same time the sample test is completed and results reported to the customer. The associated costs incurred in connection with these services is recorded as costs of revenue. The Company records revenue for these services on a gross basis as it has determined it is the principal under these arrangements. The Company also provides expert testimony, when and if necessary, to support the results of the tests, which is generally billed separately and recognized as the services are provided. Research and Development Expenses The Company expenses all research and development costs as incurred. Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes” December 31, 2016, 2015 17, Income Taxes - Balance Sheet Classification of Deferred Taxes Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no may not not not Significant Customers The Company had one 10% December 31, 2017 2016. no 10% December 31, 2015. one 23%, 34% 11% December 31, 2017, 2016 2015 Comprehensive Income The Company’s comprehensive income was $5.9 December 31, 2017 December 31, 2016 2015. Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation — Stock Compensation” 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by income statement account is as follows: Year Ended December 31, 2017 2016 2015 Cost of revenues $ 71 $ 88 $ 101 General & administrative 398 420 433 Marketing and selling 55 116 108 Research and development 58 47 32 Total stock compensation $ 582 $ 671 $ 674 See Note 7 Basic and Diluted Net Income per Share Basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows: 2017 2016 2015 Weighted average common shares outstanding, basic 5,480 5,447 5,405 Dilutive common equivalent shares 60 28 7 Weighted average common shares outstanding, assuming dilution 5,540 5,475 5,412 There were no December 31, 2017 2016. December 31, 2015, 81 not Financial Instruments Financial instruments include cash and accounts receivable and accounts payable. Estimated fair values of these financial instruments approximate carrying values due to their short-term nature. The Company has three 30 2.00%, one 30 1.75%. Basis of Preparation and Consolidation The consolidated financial statements, include the financial statements of the Company and its subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). The financial statements of the Company and its subsidiary companies have been consolidated on a line-by-line basis by adding together like items of assets, liabilities, income and expenses. All intercompany transactions and balances have been eliminated. Foreign Currency Translation The functional currency of our Brazil subsidiary is the Brazilian Real. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at the consolidated balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities that are in the functional currency is included as a component of shareholders’ equity in accumulated other comprehensive income (loss). The total change in foreign currency translation adjustment for the year ended December 31, 2017 $238 $157 Segment Reporting The Company manages its operations as one 12 Subsequent Events On March 7, 2018, $0.15 $824, March 29, 2018 March 19, 2018. Recent Accounting Pronouncements In February 2016, 2016 02, Leases 12 December 15, 2018 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 2014 09 five may The standard’s implementation date, as amended by ASU 2015 14, December 15, 2017, 2014 09 2014 09 not

Note 3 - Accounts Recievable

Note 3 - Accounts Recievable	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	3. The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts: As of December 31, 2017 2016 Balance, beginning of period $ 50 $ 59 Provision for (recoveries of) doubtful accounts 30 16 Write-offs (16 ) (25 ) Balance, end of period $ 64 $ 50

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued expenses consist of the following: As of December 31, 2017 2016 Accrued payroll and employee benefits $ 291 $ 311 Accrued bonus expense 290 407 Accrued vacation expense 481 431 Accrued taxes 1,086 288 Accrued shipping expense 364 - Deferred revenue 78 125 Other accrued expenses 280 426 Total Accrued Expenses $ 2,870 $ 1,988

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. The income tax provision consists of the following: As of December 31, 2017 2016 2015 Current – Federal $ 2,507 $ 3,016 $ (214 ) State 101 114 (55 ) Foreign 898 - - 3,506 3,130 (269 ) Deferred – Federal (1,326 ) 279 544 State (124 ) (111 ) (439 ) Foreign - - - (1,450 ) 168 105 Income Tax Provision $ 2,056 $ 3,298 $ (164 ) A reconciliation of the effective rate with the federal statutory rate is as follows: 2017 2016 2015 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit -0.2 % 0.1 % -22.0 % Permanent differences 0.4 % 0.1 % 1.3 % Stock based compensation -0.7 % 0.0 % 3.9 % Federal R&D Credits -1.3 % -1.1 % -29.4 % Foreign Taxes 7.1 % 0.0 % 0.0 % Federal Deferred Rate Decrease -14.2 % 0.0 % 0.0 % Effective tax rate 25.1 % 33.1 % -12.2 % On December 22, 2017, 2017, not 2018 35% 21%. 21%. $1.2 14.2 7.1% December 31, 2015, 12.2% December 31, 2017, no 2016. December 31, 2017, $731 2012 2017 On December 22, 2017, No. 118, 118” not At December 31, 2017, not one December 31, 2017, no may The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows: Year Ended December 31, 2017 2016 Net deferred tax liability: Excess of tax over book depreciation and amortization $ (1,980 ) $ (3,321 ) Prepaid expenses (39 ) (55 ) Allowance for doubtful accounts 14 18 Accrued expenses 105 133 Stock-based compensation 79 135 R&D tax credits 578 397 Net deferred tax liabilities $ (1,243 ) $ (2,693 ) ASC 740 two first not second 50% may may not 2016, No 2015 17, Income Taxes - Balance Sheet Classification of Deferred Taxes The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may may not December 31, 2017 2016. December 31, 2014 December 31, 2017

Note 6 - Preferred Stock

Note 6 - Preferred Stock	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Preferred Stock [Text Block]	6. The Board of Directors has the authority to designate authorized preferred shares in one no

Note 7 - Stock-based Awards

Note 7 - Stock-based Awards	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. The 2006 2006, 2011, ten 2016, 2006 500 850 December 31, 2017, 199 2006 The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs vest over a period of two four 2016 09 2016, no On May 4, 2017, 12.5 121 two four two four September 15, 2015 five 10 No 2006 The following table represents all shares granted by the Company under the 2006 three Grant Date Type Shares Fair Value (1) May 4, 2017 Options 121 $ 4.46 May 4, 2017 SUA 13 $ 18.87 May 12, 2016 Options 121 $ 2.34 May 12, 2016 SUA 17 $ 13.82 September 15, 2015 Options 47 $ 1.91 September 15, 2015 SUA 1 $ 10.21 April 29, 2015 SUA 44 $ 16.10 ( 1 The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 September 15, 2015 $1.91 $10.21 6.5 36% 2.2% 6.0% May 12, 2016 $2.34 $13.82 6.25 33% 1.75% 5.6% May 4, 2017 $4.46 $18.87 6.25 37% 2.75% 4.7% A summary of the Company’s stock option activity is as follows: Number of Weighted Ave. Aggregate (2) Outstanding, December 31, 2016 160 $ 12.76 $ 1,907 Granted 121 $ 18.87 Exercised (2 ) $ 13.82 Forfeited - $ - Outstanding, December 31, 2017 279 $ 15.40 $ 1,436 Exercisable, December 31, 2017 56 $ 446 ( 2 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 December 31, 2017 2016 $20.56 $24.68, There were 2.5 2006 December 31, 2017. no 2006 December 31, 2016 2015. 134 41 December 31, 2016 2015, 56 December 31, 2017 9 December 31, 2016. A summary of the Company’s stock unit award activity is as follows: Weighted Weighted Number of Average Price Average Fair Shares per Share (3) Value (3) Outstanding & Unvested, December 31, 2016 74 $ 14.62 $ 1,077 Granted 13 $ 18.87 $ 236 Converted to common stock (10 ) $ 13.84 $ (138 ) Cancelled (15 ) $ 16.15 $ (241 ) Forfeited (29 ) $ 14.25 $ (418 ) Outstanding & Unvested, December 31, 2017 33 $ 16.08 $ 516 ( 3 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The Weighted average fair value is the weighted average share price times the number of shares. The fair value of stock unit award vesting was $677 $691 $641 December 31, 2017, 2016 2015, $776 $727 $824 December 31, 2017, 2016 2015, As of December 31, 2017, 508 2006 December 31, 2017, $938 2.8

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	8. The Psychemedics Corporation 401 401 401 21 401 may, not $246 $246 $242 December 31, 2017, 2016 2015,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through February 2023. $0.9 $0.9 $1.0 2017, 2016 2015, At December 31, 2017, Years Ending December 31: 2018 $ 928 2019 574 2020 485 2021 108 2022 108 2023 18 Total $ 2,221 Contingencies The Company is subject legal proceedings and claims in the ordinary course of its business. The Company believes that although there can be no not

Note 10 - Debt and Other Financ

Note 10 - Debt and Other Financing Agreements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	10. On March 20, 2014, August 8, 2014, September 15, 2015 October 30, 2017, $12.8 60 30 2.00% October 2017 30 1.75% October 2017. 60 first December 31, 2017. December 31, 2017 $6.9 Under the Equipment Loan Arrangement, the Company executed notes on March 24, 2014, May 22, 2014, June 13, 2014, August 8, 2014, September 15, 2015, March 23, 2016 November 10, 2017 $1.1 $1.9 $3.0 $1.0 $1.1 $610 $2.1 $10.8 $2.1 $3.1 2017 2016, December 31, 2017, $1.9 December 31, 2017 3.0% $72 December 31, 2017, 3.3%. The annual principal repayment requirements for debt obligations as of December 31, 2017 2018 $ 957 2019 891 2020 702 2021 446 2022 381 Total long-term debt 3,377 Less current portion of long-term debt (957 ) Total long-term debt, net of current portion $ 2,420

Note 11 - Selected Quarterly Fi

Note 11 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	11. The following are selected quarterly financial data for the years ended December 31, 2017 2016: Quarter Ended - 2017 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 10,209 $ 9,684 $ 10,049 $ 9,760 Gross profit 5,316 4,609 5,121 4,777 Income from operations 2,268 1,710 2,232 1,947 Net income 1,500 907 1,364 2,350 Basic net income per share $ 0.27 $ 0.17 $ 0.25 $ 0.43 Diluted net income per share $ 0.27 $ 0.16 $ 0.25 $ 0.42 Quarter Ended - 2016 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 6,667 $ 9,700 $ 11,849 $ 10,764 Gross profit 2,738 5,209 7,105 6,398 Income (loss) from operations (2 ) 2,371 4,104 3,637 Net income (loss) (23 ) 1,633 2,708 2,360 Basic net income per share $ 0.00 $ 0.30 $ 0.49 $ 0.44 Diluted net income per share $ 0.00 $ 0.30 $ 0.49 $ 0.43

Note 12 - Business Segment Repo

Note 12 - Business Segment Reporting	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	12. The Company manages its operations as one one 10% Year Ended December 31, 2017 2016 2015 Consolidated Revenue: United States $ 26,327 $ 25,608 $ 25,836 Brazil 13,069 13,083 746 Other Foreign Countries 305 289 393 Total Revenue $ 39,701 $ 38,980 $ 26,975

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents All highly liquid investments with original maturities of 90 December 31, 2017, $4.6 December 31, 2016 2015, no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures 820” 820 820 three first two may Level 1 Level 2 1 Level 3 no A financial instrument’s level is based on the lowest level of any input that is significant to the fair value measurement.
Inventory, Policy [Policy Text Block]	Inventory Some materials used in the provision of services to our customers are included in prepaid expenses and recorded to cost of revenues upon use. Most consumables such as chemicals, antibodies and tubes are expensed as purchased.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software (in years) 3 to 5 Office furniture and equipment (in years) 3 to 7 Laboratory equipment (in years) 5 to 7 Leasehold improvements (in years) Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.8 $2.3 $1.7 2017, 2016 2015 December 31, 2017 2016, $0.5 $1.2 not
Research, Development, and Computer Software, Policy [Policy Text Block]	Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for 5 December 31, 2017, 2016 2015, $511, $315 $364, $418, $435 $422 2017, 2016, 2015, may
Other Assets [Policy Text Block]	Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2017, 2016, 2015 $711, $715 $670, $37, $36, $32 2017, 2016 2015, $50 five
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. The Company records revenue for the shipping of samples from the customer or independent hair collection facility to the laboratory for customers that choose to use the Company’s shipping account. The Company also records revenue for the collection of the hair sample for customers that choose to have the Company manage this process at the same time the sample test is completed and results reported to the customer. The associated costs incurred in connection with these services is recorded as costs of revenue. The Company records revenue for these services on a gross basis as it has determined it is the principal under these arrangements. The Company also provides expert testimony, when and if necessary, to support the results of the tests, which is generally billed separately and recognized as the services are provided.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses The Company expenses all research and development costs as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes” December 31, 2016, 2015 17, Income Taxes - Balance Sheet Classification of Deferred Taxes
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no may not not not
Major Customers, Policy [Policy Text Block]	Significant Customers The Company had one 10% December 31, 2017 2016. no 10% December 31, 2015. one 23%, 34% 11% December 31, 2017, 2016 2015
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income The Company’s comprehensive income was $5.9 December 31, 2017 December 31, 2016 2015.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation — Stock Compensation” 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by income statement account is as follows: Year Ended December 31, 2017 2016 2015 Cost of revenues $ 71 $ 88 $ 101 General & administrative 398 420 433 Marketing and selling 55 116 108 Research and development 58 47 32 Total stock compensation $ 582 $ 671 $ 674 See Note 7
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income per Share Basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows: 2017 2016 2015 Weighted average common shares outstanding, basic 5,480 5,447 5,405 Dilutive common equivalent shares 60 28 7 Weighted average common shares outstanding, assuming dilution 5,540 5,475 5,412 There were no December 31, 2017 2016. December 31, 2015, 81 not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments Financial instruments include cash and accounts receivable and accounts payable. Estimated fair values of these financial instruments approximate carrying values due to their short-term nature. The Company has three 30 2.00%, one 30 1.75%.
Basis of Presentation and Consolidation, Policy [Policy Text Block]	Basis of Preparation and Consolidation The consolidated financial statements, include the financial statements of the Company and its subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). The financial statements of the Company and its subsidiary companies have been consolidated on a line-by-line basis by adding together like items of assets, liabilities, income and expenses. All intercompany transactions and balances have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of our Brazil subsidiary is the Brazilian Real. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at the consolidated balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities that are in the functional currency is included as a component of shareholders’ equity in accumulated other comprehensive income (loss). The total change in foreign currency translation adjustment for the year ended December 31, 2017 $238 $157
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company manages its operations as one 12
Subsequent Events, Policy [Policy Text Block]	Subsequent Events On March 7, 2018, $0.15 $824, March 29, 2018 March 19, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, 2016 02, Leases 12 December 15, 2018 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 2014 09 five may The standard’s implementation date, as amended by ASU 2015 14, December 15, 2017, 2014 09 2014 09 not

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer software (in years) 3 to 5 Office furniture and equipment (in years) 3 to 7 Laboratory equipment (in years) 5 to 7 Leasehold improvements (in years) Lesser of estimated useful life or lease term
Schedule of Stock Based Compensation Expense [Table Text Block]	Year Ended December 31, 2017 2016 2015 Cost of revenues $ 71 $ 88 $ 101 General & administrative 398 420 433 Marketing and selling 55 116 108 Research and development 58 47 32 Total stock compensation $ 582 $ 671 $ 674
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2017 2016 2015 Weighted average common shares outstanding, basic 5,480 5,447 5,405 Dilutive common equivalent shares 60 28 7 Weighted average common shares outstanding, assuming dilution 5,540 5,475 5,412

Note 3 - Accounts Recievable (T

Note 3 - Accounts Recievable (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Credit Losses for Financing Receivables, Current [Table Text Block]	As of December 31, 2017 2016 Balance, beginning of period $ 50 $ 59 Provision for (recoveries of) doubtful accounts 30 16 Write-offs (16 ) (25 ) Balance, end of period $ 64 $ 50

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, 2017 2016 Accrued payroll and employee benefits $ 291 $ 311 Accrued bonus expense 290 407 Accrued vacation expense 481 431 Accrued taxes 1,086 288 Accrued shipping expense 364 - Deferred revenue 78 125 Other accrued expenses 280 426 Total Accrued Expenses $ 2,870 $ 1,988

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	As of December 31, 2017 2016 2015 Current – Federal $ 2,507 $ 3,016 $ (214 ) State 101 114 (55 ) Foreign 898 - - 3,506 3,130 (269 ) Deferred – Federal (1,326 ) 279 544 State (124 ) (111 ) (439 ) Foreign - - - (1,450 ) 168 105 Income Tax Provision $ 2,056 $ 3,298 $ (164 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2017 2016 2015 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit -0.2 % 0.1 % -22.0 % Permanent differences 0.4 % 0.1 % 1.3 % Stock based compensation -0.7 % 0.0 % 3.9 % Federal R&D Credits -1.3 % -1.1 % -29.4 % Foreign Taxes 7.1 % 0.0 % 0.0 % Federal Deferred Rate Decrease -14.2 % 0.0 % 0.0 % Effective tax rate 25.1 % 33.1 % -12.2 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2017 2016 Net deferred tax liability: Excess of tax over book depreciation and amortization $ (1,980 ) $ (3,321 ) Prepaid expenses (39 ) (55 ) Allowance for doubtful accounts 14 18 Accrued expenses 105 133 Stock-based compensation 79 135 R&D tax credits 578 397 Net deferred tax liabilities $ (1,243 ) $ (2,693 )

Note 7 - Stock-based Awards (Ta

Note 7 - Stock-based Awards (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Grant Date Type Shares Fair Value (1) May 4, 2017 Options 121 $ 4.46 May 4, 2017 SUA 13 $ 18.87 May 12, 2016 Options 121 $ 2.34 May 12, 2016 SUA 17 $ 13.82 September 15, 2015 Options 47 $ 1.91 September 15, 2015 SUA 1 $ 10.21 April 29, 2015 SUA 44 $ 16.10
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted Ave. Aggregate (2) Outstanding, December 31, 2016 160 $ 12.76 $ 1,907 Granted 121 $ 18.87 Exercised (2 ) $ 13.82 Forfeited - $ - Outstanding, December 31, 2017 279 $ 15.40 $ 1,436 Exercisable, December 31, 2017 56 $ 446
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted Weighted Number of Average Price Average Fair Shares per Share (3) Value (3) Outstanding & Unvested, December 31, 2016 74 $ 14.62 $ 1,077 Granted 13 $ 18.87 $ 236 Converted to common stock (10 ) $ 13.84 $ (138 ) Cancelled (15 ) $ 16.15 $ (241 ) Forfeited (29 ) $ 14.25 $ (418 ) Outstanding & Unvested, December 31, 2017 33 $ 16.08 $ 516

Note 9 - Commitments and Cont26

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Years Ending December 31: 2018 $ 928 2019 574 2020 485 2021 108 2022 108 2023 18 Total $ 2,221

Note 10 - Debt and Other Fina27

Note 10 - Debt and Other Financing Agreements (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2018 $ 957 2019 891 2020 702 2021 446 2022 381 Total long-term debt 3,377 Less current portion of long-term debt (957 ) Total long-term debt, net of current portion $ 2,420

Note 11 - Selected Quarterly 28

Note 11 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	Quarter Ended - 2017 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 10,209 $ 9,684 $ 10,049 $ 9,760 Gross profit 5,316 4,609 5,121 4,777 Income from operations 2,268 1,710 2,232 1,947 Net income 1,500 907 1,364 2,350 Basic net income per share $ 0.27 $ 0.17 $ 0.25 $ 0.43 Diluted net income per share $ 0.27 $ 0.16 $ 0.25 $ 0.42 Quarter Ended - 2016 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 6,667 $ 9,700 $ 11,849 $ 10,764 Gross profit 2,738 5,209 7,105 6,398 Income (loss) from operations (2 ) 2,371 4,104 3,637 Net income (loss) (23 ) 1,633 2,708 2,360 Basic net income per share $ 0.00 $ 0.30 $ 0.49 $ 0.44 Diluted net income per share $ 0.00 $ 0.30 $ 0.49 $ 0.43

Note 12 - Business Segment Re29

Note 12 - Business Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2017 2016 2015 Consolidated Revenue: United States $ 26,327 $ 25,608 $ 25,836 Brazil 13,069 13,083 746 Other Foreign Countries 305 289 393 Total Revenue $ 39,701 $ 38,980 $ 26,975

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, shares in Thousands, $ in Thousands	Feb. 14, 2018USD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Certificates of Deposit, at Carrying Value		$ 4,600
Depreciation, Depletion and Amortization, Nonproduction		2,800	$ 2,300	$ 1,700
Public Utilities, Property, Plant and Equipment, Equipment		500	$ 1,200
Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent		$ 5,900
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		0	0	81
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent		$ (238)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		$ (157)
Number of Operating Segments		1
Common Stock, Dividends, Per Share, Declared | $ / shares		$ 0.60	$ 0.60	$ 0.60
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared | $ / shares	$ 0.15
Dividends Payable	$ 824
Dividends Payable, Date to be Paid	Mar. 9, 2018
Dividends Payable, Date of Record	Feb. 26, 2018
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage		23.00%	34.00%	11.00%
Credit Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk, Percentage		10.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Number of Major Customers		1	1
Patents [Member]
Amortization		$ 37	$ 36	$ 32
Finite-Lived Intangible Asset, Useful Life		20 years
Legal Cost Capitalized		$ 711	715	670
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months		50
Finite-Lived Intangible Assets, Amortization Expense, Year Two		50
Finite-Lived Intangible Assets, Amortization Expense, Year Three		50
Finite-Lived Intangible Assets, Amortization Expense, Year Four		50
Finite-Lived Intangible Assets, Amortization Expense, Year Five		$ 50
Software Development [Member]
Property, Plant and Equipment, Useful Life		5 years
Software Development Cost Capitalized		$ 511	315	364
Amortization		$ 418	$ 435	$ 422

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)	12 Months Ended
	Dec. 31, 2017
Minimum [Member] | Office Equipment [Member]
Computer software (in years) (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Computer software (in years) (Year)	5 years
Minimum [Member] | Computer Software, Intangible Asset [Member]
Computer software (in years) (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Computer software (in years) (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Computer software (in years) (Year)	7 years
Maximum [Member] | Computer Software, Intangible Asset [Member]
Computer software (in years) (Year)	5 years

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock compensation expense	$ 582	$ 671	$ 674
Cost of Sales [Member]
Stock compensation expense	71	88	101
General and Administrative Expense [Member]
Stock compensation expense	398	420	433
Selling and Marketing Expense [Member]
Stock compensation expense	55	116	108
Research and Development Expense [Member]
Stock compensation expense	$ 58	$ 47	$ 32

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted average common shares outstanding, basic (in shares)	5,480	5,447	5,405
Dilutive common equivalent shares (in shares)	60	28	7
Weighted average common shares outstanding, assuming dilution (in shares)	5,540	5,475	5,412

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance, beginning of period	$ 50	$ 59
Provision for (recoveries of) doubtful accounts	30	16
Write-offs	(16)	(25)
Balance, end of period	$ 64	$ 50

Note 4 - Accrued Expenses - Sum

Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued payroll and employee benefits	$ 291	$ 311
Accrued bonus expense	290	407
Accrued vacation expense	481	431
Accrued taxes	1,086	288
Accrued shipping expense	364
Deferred revenue	78	125
Other accrued expenses	280	426
Total Accrued Expenses	$ 2,870	$ 1,988

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		34.00%	34.00%	34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		$ (1,200)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent		(14.20%)	0.00%	0.00%
Income Tax Reconciliation, Foreign Income Tax Witholdings		7.10%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Percent		25.10%	33.10%	(12.20%)
Income Tax Examination, Penalties and Interest Accrued		$ 0	$ 0
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member]
Tax Credit Carryforward, Amount		0
California Franchise Tax Board [Member] | State and Local Jurisdiction [Member]
Tax Credit Carryforward, Amount		$ 731
Maximum [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Minimum [Member] | Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Note 5 - Income Taxes - Summary

Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Federal	$ 2,507	$ 3,016	$ (214)
State	101	114	(55)
Foreign	898
Total Current	3,506	3,130	(269)
Federal	(1,326)	279	544
State	(124)	(111)	(439)
Foreign
Total Deffered	(1,450)	168	105
Income Tax Provision	$ 2,056	$ 3,298	$ (164)

Note 5 - Income Taxes - Reconci

Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Federal statutory rate	34.00%	34.00%	34.00%
State income taxes, net of federal benefit	(0.20%)	0.10%	(22.00%)
Permanent differences	0.40%	0.10%	1.30%
Stock based compensation	(0.70%)	0.00%	3.90%
Federal R&D Credits	(1.30%)	(1.10%)	(29.40%)
Foreign Taxes	7.10%	0.00%	0.00%
Federal Deferred Rate Decrease	14.20%	0.00%	0.00%
Federal Deferred Rate Decrease	(14.20%)	0.00%	0.00%
Effective tax rate	25.10%	33.10%	(12.20%)

Note 5 - Income Taxes - Compone

Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Net deferred tax liability:
Excess of tax over book depreciation and amortization	$ (1,980)	$ (3,321)
Prepaid expenses	(39)	(55)
Allowance for doubtful accounts	14	18
Accrued expenses	105	133
Stock-based compensation	79	135
R&D tax credits	578	397
Net deferred tax liabilities	$ (1,243)	$ (2,693)

Note 7 - Stock-based Awards (De

Note 7 - Stock-based Awards (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 04, 2017	May 12, 2016	Sep. 15, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				199,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	121,000			121,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share Price	$ 4.46	$ 2.34	$ 1.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 18.87	$ 13.82	$ 10.21
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 91 days	6 years 91 days	6 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	37.00%	33.00%	36.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.75%	1.75%	2.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	4.70%	5.60%	6.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				2,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				56,000	9,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 677	$ 691	$ 641
Conversion of Stock, Amount Issued				$ 776	$ 727	$ 824
Non-Employee Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	2 years
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	4 years
Stock Unit Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	12,500
Employee Stock Option [Member]
Share Price				$ 20.56	$ 24.68
Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				2,500	0	0
Common Stock, Capital Shares Reserved for Future Issuance				508,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 938
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				2 years 292 days
Expired Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					134,000	41,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				500,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				850,000

Note 7 - Stock-based Awards - S

Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) - $ / shares		May 04, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		121,000	121,000
Fair value per share (in dollars per share)			$ 18.87
May 4, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			121,000
Fair value per share (in dollars per share)	[1]		$ 4.46
May 4, 2017 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			13,000
Fair value per share (in dollars per share)	[1]		$ 18.87
May 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			121,000
Fair value per share (in dollars per share)	[1]		$ 2.34
May 12, 2016 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			17,000
Fair value per share (in dollars per share)	[1]		$ 13.82
September 15, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			47,000
Fair value per share (in dollars per share)	[1]		$ 1.91
September 15, 2015 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000
Fair value per share (in dollars per share)	[1]		$ 10.21
April 29, 2015 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			44,000
Fair value per share (in dollars per share)	[1]		$ 16.10
[1]	The fair value for the SUA's is the closing price of the Company's stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years and the fair value calculated using a Black-Scholes model. The options granted on September 15, 2015 have a fair value of $1.91 per share based on the $10.21 grant date and exercise prices and assuming a 6.5 year estimated term, 36% volatility, 2.2% interest rate and a 6.0% dividend yield rate. The options granted on May 12, 2016 have a fair value of $2.34 per share based on the $13.82 grant date and exercise prices and assuming a 6.25 year estimated term, 33% volatility, 1.75% interest rate and a 5.6% dividend yield rate. The options granted on May 4, 2017 have a fair value of $4.46 per share based on the $18.87 grant date and exercise prices and assuming a 6.25 year estimated term, 37% volatility, 2.75% interest rate and a 4.7% dividend yield rate.

Note 7 - Stock-based Compensati

Note 7 - Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		May 04, 2017	Dec. 31, 2017	Dec. 31, 2016
Outstanding (in shares)			160,000
Outstanding, weighted average exercise price (in dollars per share)			$ 12.76
Outstanding, aggregate intrinsic value	[1]		$ 1,436	$ 1,907
Granted (in shares)		121,000	121,000
Granted, weighted average exercise price (in dollars per share)			$ 18.87
Exercised (in shares)			(2,000)
Exercised, weighted average exercise price (in dollars per share)			$ 13.82
Forfeited (in shares)
Forfeited, weighted average exercise price (in dollars per share)
Outstanding (in shares)			279,000	160,000
Outstanding, weighted average exercise price (in dollars per share)			$ 15.40	$ 12.76
Exercisable (in shares)			56,000	9,000
Exercisable, weighted average exercise price (in dollars per share)
Exercisable, aggregate intrinsic value	[1]		$ 446
[1]	The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company's stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2017 and 2016 was $20.56 and $24.68, respectively.

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation - Nonvested Award Activity (Details) - Stock Unit Award [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Outstanding & Unvested (in shares)		74
Outstanding & Unvested, weighted average price per share (in dollars per share)	[1]	$ 14.62
Outstanding & Unvested, weighted average fair value	[1]	$ 516	$ 1,077
Granted (in shares)		13
Granted, weighted average price per share (in dollars per share)	[1]	$ 18.87
Granted, weighted average fair value	[1]	$ 236
Converted to common stock (in shares)		(10)
Converted to common stock, weighted average price per share (in dollars per share)		$ 13.84
Converted to common stock, weighted average fair value	[1]	$ (138)
Cancelled (in shares)		(15)
Cancelled, weighted average price per share (in dollars per share)		$ 16.15
Cancelled, weighted average fair value	[1]	$ (241)
Forfeited (in shares)		(29)
Forfeited, weighted average price per share (in dollars per share)		$ 14.25
Forfeited, weighted average fair value	[1]	$ (418)
Outstanding & Unvested (in shares)		33
Outstanding & Unvested, weighted average price per share (in dollars per share)	[1]	$ 16.08
[1]	Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The Weighted average fair value is the weighted average share price times the number of shares.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 246	$ 246	$ 242

Note 9 - Commitments and Cont45

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Rent Expense	$ 0.9	$ 0.9	$ 1

Note 9 - Commitments and Cont46

Note 9 - Commitments and Contingencies - Future Minimum Payments Due (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 928
2,019	574
2,020	485
2,021	108
2,022	108
2,023	18
Total	$ 2,221

Note 10 - Debt and Other Fina47

Note 10 - Debt and Other Financing Agreements (Details Textual) - USD ($) $ in Thousands	Nov. 10, 2017	Mar. 23, 2016	Sep. 15, 2015	Aug. 08, 2014	Jun. 13, 2014	May 22, 2014	Mar. 24, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Proceeds from Issuance of Long-term Debt								$ 2,078	$ 610	$ 1,097
Repayments of Long-term Debt								2,082	3,120	$ 1,455
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity								12,800			$ 12,800
Debt Instrument, Collateral Amount								6,900			6,900
Proceeds from Issuance of Long-term Debt	$ 2,100	$ 610	$ 1,100	$ 1,000	$ 3,000	$ 1,900	$ 1,100				10,800
Repayments of Long-term Debt								2,100	$ 3,100
Line of Credit Facility, Remaining Borrowing Capacity								$ 1,900			$ 1,900
Debt Instrument, Interest Rate During Period								3.00%
Interest Expense								$ 72
Debt, Weighted Average Interest Rate								3.30%			3.30%
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement, Loans prior to 2017 [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate								2.00%
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement, Loan Made After October 2017 [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate								1.75%

Note 10 - Debt and Other Fina48

Note 10 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
2,018	$ 957
2,019	891
2,020	702
2,021	446
2,022	381
Total long-term debt	3,377
Less current portion of long-term debt	(957)	$ (1,144)
Total long-term debt, net of current portion	$ 2,420	$ 2,237

Note 11 - Selected Quarterly 49

Note 11 - Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 9,760	$ 10,049	$ 9,684	$ 10,209	$ 10,764	$ 11,849	$ 9,700	$ 6,667	$ 39,701	$ 38,980	$ 26,975
Gross profit	4,777	5,121	4,609	5,316	6,398	7,105	5,209	2,738	19,822	21,450	12,717
Income from operations	1,947	2,232	1,710	2,268	3,637	4,104	2,371	(2)	8,157	10,110	1,471
Net income	$ 2,350	$ 1,364	$ 907	$ 1,500	$ 2,360	$ 2,708	$ 1,633	$ (23)	$ 6,121	$ 6,678	$ 1,511
Basic net income per share (in dollars per share)	$ 0.43	$ 0.25	$ 0.17	$ 0.27	$ 0.44	$ 0.49	$ 0.30	$ 0	$ 1.12	$ 1.23	$ 0.28
Diluted net income per share (in dollars per share)	$ 0.42	$ 0.25	$ 0.16	$ 0.27	$ 0.43	$ 0.49	$ 0.30	$ 0	$ 1.10	$ 1.22	$ 0.28

Note 12 - Business Segment Re50

Note 12 - Business Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2017
Number of Operating Segments	1
Credit Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk, Percentage	10.00%

Note 12 - Business Segment Re51

Note 12 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 39,701	$ 38,980	$ 26,975
UNITED STATES
Revenues	26,327	25,608	25,836
BRAZIL
Revenues	13,069	13,083	746
Other Foreign Countries [Member]
Revenues	$ 305	$ 289	$ 393